Literature DB >> 16544259

Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons.

R A Lempicki1, M A Polis, J Yang, M McLaughlin, C Koratich, D W Huang, B Fullmer, L Wu, C A Rehm, H Masur, H C Lane, K E Sherman, A S Fauci, S Kottilil.   

Abstract

Therapy for hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients results in modest cure rates. Gene expression patterns in peripheral blood mononuclear cells from 29 patients coinfected with HIV and HCV were used to predict virological response to therapy for HCV infection. Prediction analysis using pretherapy samples identified 79 genes that correctly classified all 10 patients who did not respond to therapy, 8 of 10 patients with a response at the end of treatment, and 7 of 9 patients with sustained virological response (86% overall). Analysis of 17 posttreatment samples identified 105 genes that correctly classified all 9 patients with response at the end of treatment and 7 of 8 patients with sustained virological response (94% overall). Failure of anti-HCV therapy was associated with elevated expression of interferon-stimulated genes. Gene expression patterns may provide a tool to predict anti-HCV therapeutic response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16544259     DOI: 10.1086/501365

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

Review 1.  The role of cytokines in the pathogenesis and treatment of HIV infection.

Authors:  Marta Catalfamo; Cecile Le Saout; H Clifford Lane
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-26       Impact factor: 7.638

2.  Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Authors:  Joseph Rasimas; Antonios Katsounas; Haniya Raza; Alison A Murphy; Jun Yang; Richard A Lempicki; Anu Osinusi; Henry Masur; Michael Polis; Shyam Kottilil; Donald Rosenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

3.  Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

Authors:  David M Asmuth; Robert L Murphy; Susan L Rosenkranz; Juan J L Lertora; Shyam Kottilil; Yoninah Cramer; Ellen S Chan; Robert T Schooley; Charles R Rinaldo; Nathan Thielman; Xiao-Dong Li; Sharon M Wahl; Jessica Shore; Jennifer Janik; Richard A Lempicki; Yaa Simpson; Richard B Pollard
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

Review 4.  Systems biology in immunology: a computational modeling perspective.

Authors:  Ronald N Germain; Martin Meier-Schellersheim; Aleksandra Nita-Lazar; Iain D C Fraser
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

5.  Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.

Authors:  Madeline Odigie; Anu Osinusi; Lisa Barrett; Kerry Townsend; Honghui Wang; Anthony F Suffredini; Henry Masur; Michael A Polis; Shyam Kottilil
Journal:  AIDS Res Hum Retroviruses       Date:  2014-06-30       Impact factor: 2.205

6.  Systemic cytokine and interferon responsiveness Patterns in HIV and HCV mono and co-infections.

Authors:  Rafael Fernandez-Botran; Swati Joshi-Barve; Smita Ghare; Shirish Barve; Mary Young; Michael Plankey; Jose Bordon
Journal:  J Interferon Cytokine Res       Date:  2014-06-23       Impact factor: 2.607

7.  Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.

Authors:  Yu-Jin Lee; Xiaozhen Zhang; Estefania Vazquez; Gayathri Shivasabesan; Howard A Young; Alison Murphy; Honghui Wang; Anthony F Suffredini; Ulrich Siebenlist; Shyam Kottilil
Journal:  J Interferon Cytokine Res       Date:  2013-10-30       Impact factor: 2.607

8.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

9.  Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients.

Authors:  Antonios Katsounas; Joseph J Rasimas; Joerg F Schlaak; Richard A Lempicki; Donald L Rosenstein; Shyam Kottilil
Journal:  J Med Virol       Date:  2014-04-30       Impact factor: 2.327

10.  High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.

Authors:  Veronica D Gonzalez; Karolin Falconer; Kim G Blom; Olle Reichard; Birgitte Mørn; Alex Lund Laursen; Nina Weis; Annette Alaeus; Johan K Sandberg
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.